What does this research mean for the field?

Targeting the A2B adenosine receptor with the small molecule inhibitor PSB1115 reduces pancreatic tumor growth and promotes an anti-tumor immune microenvironment by increasing CD8+ T-cell and M1-like macrophage infiltration. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

The study aims to evaluate the immunopreventative effects of the A2B adenosine receptor inhibitor PSB1115 on pancreatic ductal adenocarcinoma (PDAC).

April 5, 2026Cancer Research

Preclinical Testing of A2B Adenosine Receptor Inhibitor PSB1115 for Pancreatic Cancer...

View Full Paper

Ask AI

Bookmark

The study aims to evaluate the immunopreventative effects of the A2B adenosine receptor inhibitor PSB1115 on pancreatic ductal adenocarcinoma (PDAC).
Utilized a syngeneic KPC mouse model for PDAC.
Administered PSB1115 via oral gavage at varying frequencies.
Measured tumor sizes bi-weekly and analyzed tumor samples post-euthanasia.
Conducted immunohistochemistry to assess immune cell infiltration.
PSB1115 treatment significantly reduced tumor growth rates in the syngeneic model.
Greater tumor size reduction was observed with daily PSB1115 treatment (three-fold) compared to three times a week (two-fold).
Significant CD8+ T-cell infiltration and increased Granzyme B expression were noted in treated tumors.
PSB1115 treatment led to higher levels of CD68+ M1-like macrophages, indicating enhanced anti-tumor immune activity.

Discussion

No takes yet. Share an insight, caveat, or question.

Implication

Preclinical testing reveals PSB1115 reduces tumor growth and enhances immune response in pancreatic cancer models, suggesting therapeutic potential.

Cite This Study

Waller et al. (2026) studied this question.

synapsesocial.com/papers/69d1fc70a79560c99a0a1fa5 https://doi.org/10.1158/1538-7445.am2026-963

View Full Paper

Ask AI

Bookmark

Implication

Preclinical testing reveals PSB1115 reduces tumor growth and enhances immune response in pancreatic cancer models, suggesting therapeutic potential.

Preclinical Testing of A2B Adenosine Receptor Inhibitor PSB1115 for Pancreatic Cancer...

Key Points

Discussion

Implication

Cite This Study

Preclinical Testing of A2B Adenosine Receptor Inhibitor PSB1115 for Pancreatic Cancer...

Key Points

Discussion

Implication

Cite This Study

Also Consider

Also Consider